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Abstract
Fish oil (FO) is a commonly used supplemental source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 2
n–3 (v-3) polyunsaturated fatty acids (PUFAs) that have been shown to have a variety of health benefits considered to be
protective against cardiometabolic diseases. Although the effects of EPA and DHA on lipid metabolism have been
extensively studied, not all of the metabolic effects of FO-derived n–3 PUFAs have been characterized. Our laboratory
recently showed that a high-fructose diet in rhesusmonkeys induces the features of metabolic syndrome (MetS) similar to
those observed in humans. Thus, we specifically wanted to evaluate the effects of FO in rhesus monkeys fed a high-
fructose diet and hypothesized that FO supplementation would mitigate the development of fructose-induced insulin
resistance, dyslipidemia, and other cardiometabolic risk factors. In this study, adult monkeys (aged 12–20 y) received
either a standard unpurified diet plus 75 g fructose/d (control group; n = 9) or a standard unpurified diet, 75 g fructose/d,
and 4 g FO (16% EPA 1 11% DHA)/d (treatment group; n = 10) for 6 mo. Importantly, our results showed that daily FO
supplementation in the monkeys prevented fructose-induced hypertriglyceridemia and insulin resistance as assessed by
intravenous-glucose-tolerance testing (P # 0.05). Moreover, FO administration in the monkeys prevented fructose-
induced increases in plasma apolipoprotein (Apo)C3, ApoE, and leptin concentrations and attenuated decreases in
circulating adropin concentrations (P# 0.05). No differences between the control and FO-treatedmonkeyswere observed
in body weight, lean mass, fat mass, or fasting glucose, insulin, and adiponectin concentrations. In conclusion, FO
administration in a nonhuman primate model of diet-induced MetS ameliorates many of the adverse changes in lipid and
glucose metabolism induced by chronic fructose consumption. J. Nutr. 144: 5–11, 2014.
Introduction
The incidence and prevalence of insulin resistance and metabolic
syndrome (MetS)7 in the United States and worldwide have
increased dramatically over the past decade (1–3). We and others
have proposed that this increase may in part be attributable to
increased consumption of fructose derived from dietary sucrose
and high-fructose corn syrup (1–4). Individuals with MetS have a
higher likelihood of developing atherosclerotic cardiovascular
disease (ASCVD) and type 2 diabetes mellitus (T2DM) (1,3,5–8);
thus, safe interventions to prevent or mitigate the conditions
associated with MetS (including central adiposity, hypertension,
hypertriglyceridemia, and impaired glucose tolerance) are needed.
To date, there are no U.S. Food and Drug Administration–
approved pharmaceutical agents to treat or prevent MetS. As
such, consumers often resort to over-the-counter nutraceutical
therapies, many of which have little data to demonstrate their
efficacy. One such agent is fish oil (FO). FO is a commonly used
supplemental source of EPA (20:5n–3) and DHA (22:6n–3), 2
marine-derived n–3 PUFAs that have been shown to have a
variety of protective effects against cardiometabolic diseases
(9–11). The n–3 PUFAs are most widely known for their
TG-lowering effects (12,13), which are considered to be
primarily mediated via peroxisome proliferator-activated recep-
tor (PPAR)–dependent mechanisms (14). However, their poten-
tial ability to alleviate inflammation and increase insulin
sensitivity has become an area of interest as well (11,15).
Although the effects of EPA and DHA on lipid metabolism
have been extensively studied (16), not all of the metabolic
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effects of FO-derived n–3 PUFAs have been characterized.
Whereas EPA and DHA have been shown to prevent and
reverse insulin resistance in obese rodents fed a high-fat (17–19)
or high-sucrose (20) diet, they have not consistently shown
insulin-sensitizing effects in obese humans and those with
T2DM (21–23). Despite lowering circulating lipid concentra-
tions, supplementation with EPA or FO for 11 mo also did not
delay the onset of diabetes in University of California Davis–
T2DM rats (24), a well-characterized rodent model of T2DM
that exhibits polygenic adult-onset obesity and insulin resistance
with inadequate b-cell compensation (25). However, other data
suggest that FO-derived n–3 PUFAs may delay the development
of MetS or its progression to T2DM (26).
Our laboratory recently demonstrated that a high-fructose
diet in rhesus monkeys induces the features of MetS in humans,
including obesity, dyslipidemia (particularly hypertriglyceride-
mia), and insulin resistance (27). Thus, we specifically designed a
study to evaluate the effects of FO in rhesus monkeys fed a high-
fructose diet and hypothesized that treating rhesus monkeys
with a high-fructose diet combined with FO supplementation
would mitigate the development of dyslipidemia, insulin resis-
tance, and other associated cardiometabolic risk factors in this
model. Herein, we report our findings demonstrating that FO
prevents fructose-induced insulin resistance and hypertriglycer-
idemia in rhesus monkeys.
Materials and Methods
Animals. The rhesus monkeys used for this study were provided by and
maintained at the California National Primate Research Center at the
University of California, Davis. Protocols for all the animal studies were
approved by the University of California, Davis, Institutional Animal
Care and Use Committee and were conducted in accordance with the
USDA Animal Welfare Act and the NIHs Guide for the Care and Use of
Laboratory Animals. A total of 19 adult male rhesus monkeys, aged 12–
20 y (bodyweight: 15.66 0.4 kg), were studied. At baseline, all monkeys
had fasting plasma glucose concentrations <100 mg/dL, fasting insulin
concentrations <100 mU/mL, fasting plasma TG concentrations <100
mg/dL, and percentage body fat >20%.
Diet and energy intake measurements. A commercial monkey
unpurified diet (Advanced Protocol Old World Primate, LabDiet 5047)
was provided ad libitum to all of the monkeys. This is a grain-based
standard primate diet that provides 30% of energy as protein, 11% of
energy as fat (n–3 FAs, 0.14% of unpurified diet; n–6 FAs, 1.68% of
unpurified diet; total FAs, 1.83% of unpurified diet), and 59% of energy
as carbohydrate. In addition, following baseline measurements, all
monkeys were provided with 500 mL/d of a fruit-flavored (Kool-Aid;
Kraft Foods), 15% fructose-sweetened beverage (75 g of fructose). Ten
monkeys (treatment group) also received 4 g of FO supplementation/d.
The FO (16% EPA/11% DHA; 32.1% n–3 FAs; 2.4% n–6 FAs; 77.3%
total FAs; Jedwards International, validated by Covance) was mixed into
a treat such as ice cream, yogurt, jelly, applesauce, or pudding; and 1%
by weight of egg powder was added to make an emulsion. Then, 44 g of
the mixture containing 4 g of FO was provided to the monkeys each day.
The control monkeys received the same mixture with 4 g of safflower
oil [0.05% FFAs; 6.54% palmitic acid (16:0); 2.62% stearic acid (18:0);
14.97% oleic acid (18:1); 73.47% linoleic acid (18:2); 0.05% linolenic
acid (18:3); 0.15% behenic acid (22:0); Jedwards International] instead
of FO. Beverage intake was recorded daily, and food intake was recorded
for 1 wk at baseline, and then for another 1-wk period at 6 mo. The
monkeys were randomly assigned by age equally to the FO-treated and
control groups.
Body weight and body adiposity. Body weights of the monkeys
were determined monthly. At baseline and at 6 mo, percentage and
total body fat were determined by DXA, a sensitive technique for
measuring body fat (28) that has been previously validated for the
determination of body composition in monkeys (29).
Intravenous-glucose-tolerance tests. At baseline and at 6 mo,
intravenous-glucose-tolerance tests (IVGTTs) were performed and the
AUC for glucose and insulin calculated by using the trapezoidal method;
glucose tolerance was estimated by the area above baseline under the
glucose curve from 0 to 60 min, and an index of insulin sensitivity was
calculated as described previously (27,30).
Glucose, insulin, and HOMA-IR. Plasma insulin concentrations were
measured by using an RIA (Millipore), and plasma glucose concentra-
tions were measured with a YSI Glucose Analyzer (YSI Life Sciences).
HOMA-IR was calculated by using the following equation: ([fasting
glucose (mmol/L) 3 fasting insulin (mU/mL)]/22.5) (31).
Lipid and lipoproteins. Plasma total cholesterol, HDL cholesterol,
LDL cholesterol, TG, apoA1, apoB, apoC3, and apoE concentrations
were determined by using a Polychem Chemistry Analyzer (PolyMedCo).
Adipocyte and hepatic hormones. Plasma adiponectin and leptin
concentrations were measured by RIA (Millipore). Plasma adropin
concentrations were measured by using a commercially available
ELISA (Peninsula Laboratories, Bachem) (32). Before the analyses, all
of the antibodies were tested to ensure their ability to measure the
target hormone in samples from rhesus monkeys (27). The AUC for
adropin during the 6-mo study was calculated by using the trapezoidal
method.
TABLE 1 Effects of FO on fasting plasma lipid and lipoprotein
concentrations in rhesus monkeys fed a high-fructose diet1
Control (n = 9) FO (n = 10)
Result D Result D
mg/dL mg/dL
Cholesterol
Baseline 142 6 8 — 137 6 9 —
6 mo 146 6 8 +5 6 4 125 6 10 212 6 6
LDL-C
Baseline 70 6 6 — 66 6 7 —
6 mo 64 6 5 26 6 4 62 6 7 25 6 5
HDL-C
Baseline 55 6 3 — 54 6 4 —
6 mo 55 6 4 0 6 3 49 6 5 25 6 2*
TGs
Baseline 83 6 8 — 81 6 10 —
6 mo 136 6 22 +53 6 21* 74 6 8 27 6 7z
ApoA1
Baseline 143 6 6 — 144 6 4 —
6 mo 147 6 8 +4 6 4 132 6 6 211 6 3y
ApoB
Baseline 55 6 4 — 51 6 5 —
6 mo 56 6 4 +1 6 3 50 6 6 21 6 3
ApoC3
Baseline 2.28 6 0.19 — 2.28 6 0.19 —
6 mo 2.85 6 0.19 +0.57 6 0.13** 2.11 6 0.21 20.17 6 0.18z
ApoE
Baseline 2.12 6 0.15 — 1.92 6 0.13 —
6 mo 2.74 6 0.14 +0.62 6 0.14* 2.09 6 0.14 +0.18 6 0.11y
1 Values are means 6 SEMs. Differences in means from baseline: *P # 0.05,
**P # 0.01. Differences in means from baseline to 6 mo between control and FO
groups: yP # 0.05, zP # 0.01. FO, fish oil; HDL-C, HDL cholesterol; LDL-C, LDL
cholesterol.
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Statistical analysis. Descriptive statistics are provided for each of
the outcomes as means 6 SEMs. Within a given treatment group,
Wilcoxons Signed Rank tests were used to compare baseline data for
each outcome with the 6-mo measurements. Linear mixed models were
used to assess the longitudinal trend of each outcome and to compare the
changes in the FO treatment group compared with the control group.
Unless otherwise noted, the P values reported represent the results of the
linear mixed-model analyses. Each linear mixed model regressed a single
outcome postbaseline on time (categorical for 1, 3, and 6 mo), group,
group by time interaction, and the baseline value of the respective
outcome. Random intercepts were included to account for repeated
measures. Estimatedmean differences between groups were calculated at
1, 3, and 6 mo, adjusting for baseline values. Before the analyses, the
distributions of each outcome variable were also assessed for normality;
for those outcome variables with skewed distributions, log transforma-
tions were applied to meet the normality assumptions of the linear mixed
model. For each outcome requiring a transformation, the estimated
differences between time points were back transformed to represent
ratios of geometric means with corresponding 95% CIs and P values.
One-tailed t tests were also performed to evaluate the AUC for the
glucose and insulin excursions during the IVGTTs at baseline and 6 mo
and the AUC for the adropin concentration changes from baseline to
6 mo. Statistical analyses with P values#0.05 were considered significant.
Results
Body weight and body composition. In the control monkeys
(n = 9), body weight increased from 15.8 6 0.6 kg at baseline to
17.8 6 0.8 kg at 6 mo (+13%; P = 0.004), whereas in the
FO-treated monkeys (n = 10), body weight increased from 15.5 6
0.5 kg at baseline to 16.9 6 0.6 kg at 6 mo (+9%; P = 0.002).
Although the increase in body weight from baseline to 6 mo was
significant for each group, the mean difference in weight gain
between the control monkeys and the FO-treated monkeys was
not significant after adjusting for baseline values. Furthermore,
there were no significant differences between the 2 groups with
respect to lean body mass and fat mass.
Fasting lipid and lipoprotein concentrations. As shown in
Table 1, fasting TG and apoC3 concentrations were significantly
higher in the control group versus the FO treatment group at the
completion of the 6-mo study (P = 0.005). Specifically, in the
control monkeys, both fasting TG (+71 6 25%; Fig. 1A) and
fasting apoC3 (+28 6 8%; Fig. 1B) concentrations increased. In
contrast, both fasting TG concentrations (23 6 7%; Fig. 1A)
and fasting apoC3 concentrations (25 6 9%; Fig. 1B) were
unchanged in the monkeys that received the daily FO supple-
mentation. ApoA1 concentrations decreased modestly in the
FO-treated monkeys (28 6 2%; P = 0.018). ApoE concentrations
FIGURE 1 The effect of fish oil on fasting plasma TG (A) and
apoC3 (B) concentrations in rhesus monkeys fed a high-fructose diet
for 6 mo. Values are means 6 SEMs; n = 9 (control) or 10 (fish oil).
*Different from control, P # 0.05.
TABLE 2 Effects of FO on fasting plasma glucose and insulin concentrations, glucose tolerance, and
insulin sensitivity in rhesus monkeys fed a high-fructose diet1
Control (n = 9) FO (n = 10)
Result D Result D
Glucose, mg/dL
Baseline 68 6 4 — 87 6 5 —
6 mo 69 6 2 +1 6 3 81 6 7 26 6 7
Insulin, mU/mL
Baseline 55 6 13 — 61 6 15 —
6 mo 113 6 44 +57 6 32* 89 6 26 +28 6 27
AUC glucose, mg/dL 3 60 min
Baseline 11,002 6 536 — 11,021 6 600 —
6 mo 11,841 6 392 +839 6 611 11,545 6 332 +524 6 365
AUC insulin, mU/mL 3 60 min
Baseline 15,327 6 2406 — 16,275 6 4407 —
6 mo 28,895 6 8697 +13,568 6 7594* 17,345 6 3509 +1070 6 4280
HOMA-IR
Baseline 10.04 6 3.09 — 12.37 6 2.79 —
6 mo 19.46 6 7.99 +9.43 6 5.10 18.20 6 6.22 +5.48 6 6.71
Insulin sensitivity index
Baseline 0.63 6 0.11 — 0.76 6 0.21 —
6 mo 0.47 6 0.11 20.16 6 0.09 0.71 6 0.24 20.06 6 0.07
1 Values are means 6 SEMs. *Different from baseline, P # 0.05. FO, fish oil.
Fish oil ameliorates fructose-induced changes 7
 at UNIVERSITY O
F CALIFO
RNIA DAVIS on January 15, 2014
jn.nutrition.org
D
ow
nloaded from
 
also increased in the control group (+336 9%) more than in the
FO-treated group (+11 6 6%) (P = 0.030). Moreover, choles-
terol concentrations increased slightly in the control group (+46
3%), whereas they decreased modestly in the monkeys treated
with FO (28 6 5%) (P = 0.025, Wilcoxons rank-sum test).
Fasting glucose and insulin concentrations, glucose
tolerance, and insulin sensitivity. During the course of the
study, none of the monkeys developed frank diabetes (defined by
a fasting blood glucose concentration >125 mg/dL), and the
fasting blood glucose concentrations remained fairly stable in
both the control and FO treatment groups (Table 2). Both
groups exhibited increased fasting insulin concentrations,
suggesting b-cell compensation for insulin resistance; however,
the increase of fasting insulin concentrations in the FO-treated
monkeys tended to be smaller (+28 6 27 mg/dL) than in the
control monkeys (+57 6 32 mg/dL). Furthermore, although the
glycemic excursions and the AUC for glucose concentrations
during the IVGTTs in the control and FO treatment groups were
similar at the end of the 6-mo study (Figs. 2A and 3A), the insulin
excursions and AUC for insulin concentrations were different
(Figs. 2B and 3B). Specifically, the AUC insulin for the control
group increased by 81 6 39%, whereas the AUC insulin for the
FO-treated monkeys increased only by 30 6 27% (P = 0.037).
Adipocyte and hepatic hormones. Fasting total adiponectin
concentrations decreased comparably in both the control (2216
8%) and the FO treatment (227 6 8%) groups at the
completion of the study (Table 3). In contrast, the increase in
fasting leptin concentrations was significantly greater in the
control monkeys (+32 6 8%) than in the monkeys treated with
FO (+9 6 5%) (P = 0.033). In addition, circulating adropin
concentrations increased in the FO-treated group (+25 6 18%),
whereas they decreased in the control group (-12 6 6%)
(P = 0.042), a difference demonstrated by the AUC for plasma
adropin concentrations over the course of the study (Fig. 4).
Discussion
In this study, we demonstrated that daily FO supplementation in
rhesus monkeys prevents fructose-induced hypertriglyceridemia
and insulin resistance. Moreover, we report that FO adminis-
tration in nonhuman primates prevents fructose-induced in-
creases in apoC3 and apoE concentrations and attenuates the
increase in leptin and the decrease in adropin concentrations.
Previous studies suggest that FO, particularly the long-chain
n–3 PUFAs DHA and EPA, reduce plasma TG concentrations
primarily from the decline in hepatic VLDL-TG production, and
secondarily from an increase in VLDL-TG clearance (33).
Specifically, FO counteracts intracellular lipolysis in adipocytes
by suppressing adipose tissue inflammation, resulting in a de-
crease in the activity of hormone sensitive lipase, thereby
decreasing the availability of nonesterified fatty acids for hepatic
TG production (33). In addition, FO increases extracellular
FIGURE 2 Plasma glucose and insulin responses during an
intravenous-glucose-tolerance test (IVGTT) in control monkeys at
baseline and after 6 mo. The plasma glucose response (A) did not
differ between the 2 time points. However, the plasma insulin
response (B) during the IVGTT was significantly increased after 6 mo
consuming fructose. Values are means 6 SEMs; n = 9. *Different
AUC from baseline, P # 0.05.
FIGURE 3 Plasma glucose and insulin responses during an
intravenous-glucose-tolerance test in the FO–treated monkeys at
baseline and after 6 mo. The plasma glucose response (A) did not
differ between the 2 time points. Unlike in the control monkeys, the
plasma insulin response (B) also did not differ between the 2 time
points, demonstrating the insulin-sensitizing effects of FO. Values
are means 6 SEMs; n = 10. FO, fish oil.
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lipolysis by lipoprotein lipase, which is inhibited by apoC3.
Thus, agents that lower apoC3 concentratons would be
expected to also lower TG concentrations. Although a previous
study reported that the TG-lowering effect of an ethyl ester
preparation of FO in humans normalized elevated plasma TG
concentrations independent of its effect on apoC3 (34), our data
suggest that the FO-induced lowering of apoC3 may be a
contributing factor to the effects of FO to prevent the increase in
TG concentrations in response to dietary fructose.
In this study, we also demonstrate that FO supplementation
prevents fructose-induced insulin resistance as demonstrated by
the AUC insulin data during the IVGTTs, supporting an insulin-
sensitizing action of n–3 PUFAs.Moreover, although others have
reported that n–3 PUFAs lower increases in leptin expression in
animal models of diet-induced obesity (35), we found that FO
attenuates fructose-induced increases in leptin concentrations in
a weight-independent manner, an interesting result that requires
further investigation. Agonists of PPAR-g have been demon-
strated to increase the expression and secretion of adiponectin
(36–38) and reduce the expression and secretion of leptin (39–
41). Therefore, if FO supplementation were to elicit significant
PPAR-g activation in our rhesus monkey model, we would
expect it to also prevent or attenuate the decrease in adiponectin
observed during fructose feeding. However, the decreases in
adiponectin concentrations were similar in the control and
FO-treated monkeys. Although the results of studies investigat-
ing the effects of dietary n–3 PUFAs on circulating adiponectin
concentrations in humans have been conflicting, we have
reported that consumption of a diet high in n–3 PUFAs did not
increase either total or high-molecular-weight adiponectin in
humans over a 14-wk period (42). We also found that FO
attenuates fructose-induced decreases in circulating adropin
concentrations. Adropin is a peptide hormone produced by the
liver that appears to have a role in metabolic and glucose
homeostasis (43). Adropin deficiency is associated with in-
creased adiposity and insulin resistance (44), and adropin
concentrations increase with weight loss (32). Interestingly,
our findings suggest that FO increases circulating adropin
concentrations relative to controls and independent of changes
in body weight/adiposity, another intriguing result that requires
further investigation.
In addition, FO supplementation modestly decreased plasma
apoA1 concentrations, a finding observed in previous studies
evaluating the effect of the n–3 PUFAs on apo1 expression and
concentrations (45,46). In our study, FO supplementation also
prevented fructose-induced increases in apoE concentrations, a
positive finding with regard to cardiometabolic risk given that
high plasma apoE concentrations strongly associate with cardi-
ovascular mortality independent of APOE genotype and plasma
lipids (47). In summary, because the ratio of n–6:n–3 PUFAs
affects cardiovascular disease risk (48) and individuals with a
low n–3 index (erythrocyte EPA+DHA as a percentage of total
FAs) (49,50) have a higher risk of cardiovascular events (51), the
results of the present study indicating that FO ameliorates
multiple lipid and metabolic variables in our fructose-fed rhesus
monkey model (27) are consistent with FOs positive clinical
attributes.
Importantly, the current study reinforces the use of rhesus
monkeys as an animal model relevant to human metabolic
diseases that allows for strict control of dietary variables and
physical activity as well as the assurance of near 100% com-
pliance with an intervention. As we have demonstrated previ-
ously and in this study (27), nutritional intervention studies
conducted in rhesus monkeys can also be performed over an
extended period of time (e.g., months to years), which is not
practical nor feasible with human subjects. Moreover, this study
is, to our knowledge, the first to assess circulating adropin
concentrations in nonhuman primates and to demonstrate the
prevention of fructose-induced hypertriglyceridemia by FO in a
nonhuman primate model.
In conclusion, given the increasing incidence and prevalence
of MetS, and the lack of approved pharmaceutical agents for its
prevention, many individuals resort to the use of nutraceutical
therapies for the prevention of the syndrome or at least its many
components. FO is one of the most commonly used nutraceut-
icals and is well known as a rich source of n–3 PUFAs. Given the
many health benefits of n–3 PUFAs, mainly EPA and DHA,
interest in their biological mechanism(s) of action continues to
grow. Because we previously demonstrated that, like in humans
(52), consumption of a high-fructose diet in rhesus monkeys
produces many of components of MetS within a relatively short
(6-mo) period of time, we used this model to study the effects of
FO on the development of diet-induced metabolic disease. In this
study, we report the novel findings that FO prevents fructose-
induced hypertriglyceridemia and insulin resistance in fructose-
fed rhesus monkeys. We therefore demonstrate that the rhesus
monkey model of fructose-induced MetS is directly translatable
TABLE 3 Effects of FO on fasting plasma adipocyte and
hepatic hormones in rhesus monkeys fed a high-fructose diet1
Control (n = 9) FO (n = 10)
Result D Result D
Adiponectin, mg/mL
Baseline 5.87 6 1.01 — 6.55 6 0.71 —
6 mo 4.63 6 0.88 21.24 6 0.45* 4.71 6 0.67 21.85 6 0.68*
Leptin, mg/L
Baseline 19.01 6 1.46 — 21.49 6 2.12 —
6 mo 24.63 6 1.76 +5.62 6 1.18** 22.88 6 1.81 +1.38 6 0.83y
Adropin, mg/L
Baseline 1.92 6 0.18 — 1.65 6 0.34 —
6 mo 1.66 6 0.15 20.27 6 0.11 1.83 6 0.24 +0.16 6 0.29
1 Values are means 6 SEMs. Differences in means from baseline: *P # 0.05,
**P # 0.01. Difference in means from baseline to 6 mo between control and FO
groups: yP # 0.05. FO, fish oil.
FIGURE 4 Effect of fish oil on percentage changes of fasting plasma
adropin concentrations in rhesus monkeys fed a high-fructose diet.
Values are means 6 SEMs; n = 9 (control) or 10 (fish oil). *Different
AUC from control at 6 mo, P # 0.05.
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to the study of diet-induced MetS in humans and can be
efficiently and effectively used to investigate the metabolic
effects of pharmaceutical and nutraceutical agents and inter-
ventions for the prevention and treatment of diet-induced
dyslipidemia and insulin resistance. New studies investigating
the biochemical and molecular mechanisms underlying these
metabolic effects of FO, DHA, and EPA are thus warranted.
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